發(fā)布時間：2018-05-15 11:57

  本文選題：醫(yī)藥上市公司 + 研發(fā)投入��； 參考：《西北農(nóng)林科技大學(xué)》2017年碩士論文

【摘要】：在全球市場競爭越發(fā)激烈的今天,研發(fā)活動對于企業(yè)核心競爭力的培育發(fā)揮著越來越重要的作用。國內(nèi)外的理論和實(shí)證研究都表明,高新技術(shù)企業(yè)的研發(fā)投入與其成長性成正相關(guān)關(guān)系,與企業(yè)的盈利能力也呈正相關(guān)關(guān)系。醫(yī)藥行業(yè)恰好是技術(shù)密集型的高新技術(shù)產(chǎn)業(yè)之一,技術(shù)資本的邊際報酬遞增規(guī)律具有深厚的理論基礎(chǔ),因而對于醫(yī)藥行業(yè)來說,以藥品研發(fā)為主導(dǎo)的技術(shù)創(chuàng)新對企業(yè)長期占據(jù)有利地位和持續(xù)成長極其重要。目前我國對于企業(yè)研發(fā)投入相關(guān)數(shù)據(jù)的披露采取非強(qiáng)制性原則,許多企業(yè)基于保密考慮不予披露,因此可獲取的研發(fā)投入數(shù)據(jù)十分有限,對于研發(fā)投入與企業(yè)成長性之間關(guān)系的研究尚缺乏足夠的實(shí)證研究支持。本文在對前人研究成果歸納和整理的基礎(chǔ)上,對研發(fā)投入和企業(yè)成長性涉及的相關(guān)理論進(jìn)行整合,選取我國滬深主板上市公司中研發(fā)投入相關(guān)數(shù)據(jù)較齊全的98家醫(yī)藥企業(yè)為樣本,采用2012-2015年共四年的研究區(qū)間,運(yùn)用因子分析、描述性統(tǒng)計分析與多元線性回歸的分析方法,實(shí)證研究醫(yī)藥上市公司研發(fā)投入對企業(yè)成長性的影響作用。根據(jù)指標(biāo)可量化原則,選擇反映企業(yè)成長性的相關(guān)指標(biāo),通過因子分析得出企業(yè)成長性的指標(biāo)值作為因變量。選取研發(fā)投入強(qiáng)度和研發(fā)與技術(shù)人員比例作為自變量,將企業(yè)規(guī)模、財務(wù)杠桿、企業(yè)上市年齡作為控制變量建立多元線性回歸模型。得出研究結(jié)論:我國醫(yī)藥上市公司當(dāng)期的研發(fā)投入強(qiáng)度與企業(yè)成長性正相關(guān),并通過了顯著性檢驗(yàn);研發(fā)與技術(shù)人員比例與企業(yè)成長性不存在顯著的相關(guān)關(guān)系,沒有通過顯著性檢驗(yàn);當(dāng)期的研發(fā)投入強(qiáng)度與滯后一年、滯后兩年、滯后三年的企業(yè)成長性呈正相關(guān),說明企業(yè)的研發(fā)投入對成長性的影響有滯后性,并且由于相關(guān)系數(shù)呈現(xiàn)出減小的趨勢,說明研發(fā)投入強(qiáng)度對企業(yè)成長性的影響具有短期效應(yīng);企業(yè)規(guī)模與企業(yè)成長性正相關(guān),而財務(wù)杠桿、上市年齡與企業(yè)成長性的相關(guān)關(guān)系為負(fù)。最后,本文根據(jù)研究結(jié)論對我國醫(yī)藥企業(yè)成長提出了增加研發(fā)投入、注重研發(fā)團(tuán)隊建設(shè)、提高研發(fā)效率、完善研發(fā)投入信息披露等針對性建議。
[Abstract]:With the increasingly fierce competition in the global market, R & D activities play a more and more important role in fostering the core competitiveness of enterprises. Theoretical and empirical studies at home and abroad show that R & D investment of high-tech enterprises is positively correlated with their growth and profitability. The pharmaceutical industry happens to be one of the technology-intensive high-tech industries. The law of increasing marginal returns of technological capital has a profound theoretical foundation, so for the pharmaceutical industry, Pharmaceutical R & D-led technological innovation is very important to the long-term favorable position and sustainable growth of enterprises. At present, our country adopts the non-mandatory principle for the disclosure of data related to enterprise R & D input. Many enterprises do not disclose data on the basis of confidentiality, so the available R & D input data are very limited. The research on the relationship between R & D investment and enterprise growth is lack of sufficient empirical research support. On the basis of summing up and sorting out the previous research results, this paper integrates the related theories of R & D investment and enterprise growth. In this paper, 98 pharmaceutical companies with complete data on R & D input from Shanghai and Shenzhen main Board listed companies are selected as samples, using the research interval of four years from 2012 to 2015, using factor analysis, descriptive statistical analysis and multivariate linear regression analysis method. Empirical study on the impact of R & D investment on the growth of listed pharmaceutical companies. According to the principle of quantifiable index, this paper selects the related index which reflects the growth of enterprise, and obtains the index value of enterprise growth as dependent variable by factor analysis. Selecting R & D investment intensity and R & D / R & T ratio as independent variables, the multiple linear regression model is established by taking enterprise size, financial leverage and enterprise listing age as control variables. The conclusion of the study is: the R & D investment intensity of the listed pharmaceutical companies in the current period is positively related to the growth of the enterprises and has passed the significant test, and there is no significant correlation between the R & D and technical personnel ratio and the growth of the enterprises. The intensity of R & D investment in the current period is positively correlated with the growth of enterprises that lag behind for one year, two years, and three years, indicating that the impact of R & D investment on growth is lagging behind. Because of the decreasing trend of correlation coefficient, it shows that R & D investment intensity has short-term effect on enterprise growth, enterprise size is positively related to enterprise growth, and financial leverage, and R & D investment intensity has a short-term effect on enterprise growth. The correlation between listing age and enterprise growth is negative. Finally, according to the conclusion of the research, this paper puts forward some suggestions for the growth of Chinese pharmaceutical enterprises, such as increasing R & D investment, paying attention to R D team building, improving R D efficiency, perfecting R D investment information disclosure and so on.
【學(xué)位授予單位】：西北農(nóng)林科技大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：F426.72;F273.1;F832.51

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 楊蕙馨;王嵩;;技術(shù)創(chuàng)新能力對中小企業(yè)成長性的影響研究——以中小板制造業(yè)上市公司為例[J];東岳論叢;2013年02期

2 陳丹;張慧麗;;中小企業(yè)技術(shù)創(chuàng)新能力與成長性關(guān)系的實(shí)證研究[J];財貿(mào)研究;2011年01期

3 李明星;張同建;林昭文;;知識轉(zhuǎn)化、自主技術(shù)創(chuàng)新與企業(yè)成長的相關(guān)性研究——基于廣東省高技術(shù)風(fēng)險企業(yè)的數(shù)據(jù)檢驗(yàn)[J];科技管理研究;2010年23期

4 徐欣;唐清泉;;R&D活動、創(chuàng)新專利對企業(yè)價值的影響——來自中國上市公司的研究[J];研究與發(fā)展管理;2010年04期

5 張信東;薛艷梅;;R&D支出與公司成長性之關(guān)系及階段特征——基于分位數(shù)回歸技術(shù)的實(shí)證研究[J];科學(xué)學(xué)與科學(xué)技術(shù)管理;2010年06期

6 張信東;尚利強(qiáng);姜小麗;;企業(yè)R&D投資與市場收益關(guān)系——基于國家認(rèn)定企業(yè)技術(shù)中心的數(shù)據(jù)[J];經(jīng)濟(jì)管理;2009年03期

7 陳曉紅;彭子晟;韓文強(qiáng);;中小企業(yè)技術(shù)創(chuàng)新與成長性的關(guān)系研究——基于我國滬深中小上市公司的實(shí)證分析[J];科學(xué)學(xué)研究;2008年05期

8 李濤;黃曉蓓;王超;;企業(yè)科研投入與經(jīng)營績效的實(shí)證研究——信息業(yè)與制造業(yè)上市公司的比較[J];科學(xué)學(xué)與科學(xué)技術(shù)管理;2008年07期

9 金永紅;;我國企業(yè)R&D投入不足的原因與對策研究[J];高科技與產(chǎn)業(yè)化;2008年02期

10 胡恩華;劉洪;張龍;;我國科技投入經(jīng)濟(jì)效果的實(shí)證研究[J];科研管理;2006年04期

相關(guān)碩士學(xué)位論文 前1條

1 陳志勇;中小企業(yè)研發(fā)投入與公司業(yè)績相關(guān)性的研究[D];北京化工大學(xué);2006年

，

本文編號：1892375